Skip to main content
Top
Published in: Medical Oncology 3/2011

01-09-2011 | Original Paper

Importance of ATM gene as a susceptible trait: predisposition role of D1853N polymorphism in breast cancer

Authors: Parvin Mehdipour, Marzieh Mahdavi, Javad Mohammadi-Asl, Morteza Atri

Published in: Medical Oncology | Issue 3/2011

Login to get access

Abstract

The involvement of ATM gene and specifically, the important role of D1853N polymorphism, as a three-hit hypothesis has been previously reported in an Iranian proband affected with brain tumor and this polymorphism could be screened in her relatives as well. The aim of present study was to investigate the involvement of D1853N polymorphism as a predisposition factor in 129 Iranian patients affected with primary breast cancer and 248 sex- and age-matched healthy controls. Mutant allele-specific PCR amplification (MASA) assay was performed to analyze the D1853N polymorphism in the ATM gene. The frequency of D1853N polymorphism in cases, internal and external controls was 31.0% (40/129), 26.9% (28/104) and 12.5% (18/144), respectively. The frequency of D1853N in total control groups, including normal external control and pedigree internal control, was 18.6% (46/248). The odds ratio was calculated with the logistic regression test, with an estimated relative risk of 2.579 (P = 0.005). The significant difference was observed between the patient-carriers of this alteration and external controls (P = 0.001). The number of controls harboring D1853N polymorphism was higher in internal control compared to external controls, and the difference was statistically significant (P = 0.004). The significant difference was observed between the patient-carriers and external controls and could be considered as a predisposing and diagnostic marker in the population and specifically in the cancer-prone pedigrees.
Literature
1.
go back to reference Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, et al. Cancer incidence and mortality in Iran. Ann Oncol. 2009;20(3):556–63.PubMedCrossRef Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, et al. Cancer incidence and mortality in Iran. Ann Oncol. 2009;20(3):556–63.PubMedCrossRef
2.
go back to reference Negrini M, Rasio D, Hampton GM, Sabbioni S, Rattan S, et al. Definition and refinement of chromosome 11 regions of loss of heterozygosity in breast cancer: identification of a new region at 11q23.3. Cancer Res. 1995;55(14):3003–7.PubMed Negrini M, Rasio D, Hampton GM, Sabbioni S, Rattan S, et al. Definition and refinement of chromosome 11 regions of loss of heterozygosity in breast cancer: identification of a new region at 11q23.3. Cancer Res. 1995;55(14):3003–7.PubMed
3.
go back to reference Laake K, Launonen V, Niederacher D, Gudlaugsdottir S, Seitz S, et al. Loss of heterozygosity at 11q23.1 and survival in breast cancer: results of a large European study. Breast Cancer Somatic Genetics Consortium. Genes Chromosom Cancer. 1999;25(3):212–21.PubMedCrossRef Laake K, Launonen V, Niederacher D, Gudlaugsdottir S, Seitz S, et al. Loss of heterozygosity at 11q23.1 and survival in breast cancer: results of a large European study. Breast Cancer Somatic Genetics Consortium. Genes Chromosom Cancer. 1999;25(3):212–21.PubMedCrossRef
4.
go back to reference Hampton GM, Mannermaa A, Winqvist R, Alavaikko M, Blanco G, et al. Loss of heterozygosity in sporadic human breast carcinoma: a common region between 11q22 and 11q23.3. Cancer Res. 1994;54(17):4586–9.PubMed Hampton GM, Mannermaa A, Winqvist R, Alavaikko M, Blanco G, et al. Loss of heterozygosity in sporadic human breast carcinoma: a common region between 11q22 and 11q23.3. Cancer Res. 1994;54(17):4586–9.PubMed
5.
go back to reference Carter SL, Negrini M, Baffa R, Gillum DR, Rosenberg AL, et al. Loss of heterozygosity at 11q22–q23 in breast cancer. Cancer Res. 1994;54(23):6270–4.PubMed Carter SL, Negrini M, Baffa R, Gillum DR, Rosenberg AL, et al. Loss of heterozygosity at 11q22–q23 in breast cancer. Cancer Res. 1994;54(23):6270–4.PubMed
6.
go back to reference Sandoval N, Platzer M, Rosenthal A, Dork T, Bendix R, Skawran B, Stuhrmann M, Wegner RD, Sperling K, Banin S, Shiloh Y, Baumer A, Bernthaler U, Sennefelder H, Brohm M, Weber BH, Schindler D. Characterization of ATM gene mutations in 66 ataxia telangiectasia families. Hum Mol Genet. 1999;8(1):69–79.PubMedCrossRef Sandoval N, Platzer M, Rosenthal A, Dork T, Bendix R, Skawran B, Stuhrmann M, Wegner RD, Sperling K, Banin S, Shiloh Y, Baumer A, Bernthaler U, Sennefelder H, Brohm M, Weber BH, Schindler D. Characterization of ATM gene mutations in 66 ataxia telangiectasia families. Hum Mol Genet. 1999;8(1):69–79.PubMedCrossRef
7.
go back to reference Stilgenbauer S, Schaffner C, Litterst A, Liebisch P, Gilad S, et al. Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat Med. 1997;3(10):1155–9.PubMedCrossRef Stilgenbauer S, Schaffner C, Litterst A, Liebisch P, Gilad S, et al. Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat Med. 1997;3(10):1155–9.PubMedCrossRef
8.
go back to reference Vorechovsky I, Luo L, Dyer MJ, Catovsky D, Amlot PL, et al. Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia. Nat Genet. 1997;17(1):96–9.PubMedCrossRef Vorechovsky I, Luo L, Dyer MJ, Catovsky D, Amlot PL, et al. Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia. Nat Genet. 1997;17(1):96–9.PubMedCrossRef
9.
go back to reference Stoppa-Lyonnet D, Soulier J, Lauge A, Dastot H, Garand R, et al. Inactivation of the ATM gene in T-cell prolymphocytic leukemias. Blood. 1998;91(10):3920–6.PubMed Stoppa-Lyonnet D, Soulier J, Lauge A, Dastot H, Garand R, et al. Inactivation of the ATM gene in T-cell prolymphocytic leukemias. Blood. 1998;91(10):3920–6.PubMed
10.
go back to reference Yuille MA, Coignet LJ, Abraham SM, Yaqub F, Luo L, et al. ATM is usually rearranged in T-cell prolymphocytic leukaemia. Oncogene. 1998;16(6):789–96.PubMedCrossRef Yuille MA, Coignet LJ, Abraham SM, Yaqub F, Luo L, et al. ATM is usually rearranged in T-cell prolymphocytic leukaemia. Oncogene. 1998;16(6):789–96.PubMedCrossRef
11.
go back to reference Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971;68(4):820–3.PubMedCrossRef Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971;68(4):820–3.PubMedCrossRef
12.
go back to reference Shiloh Y, Kastan MB. ATM: genome stability, neuronal development, and cancer cross paths. Adv Cancer Res. 2001;83:209–54.PubMedCrossRef Shiloh Y, Kastan MB. ATM: genome stability, neuronal development, and cancer cross paths. Adv Cancer Res. 2001;83:209–54.PubMedCrossRef
13.
go back to reference Concannon P, Gatti RA. Diversity of ATM gene mutations detected in patients with ataxia-telangiectasia. Hum Mutat. 1997;10(2):100–7.PubMedCrossRef Concannon P, Gatti RA. Diversity of ATM gene mutations detected in patients with ataxia-telangiectasia. Hum Mutat. 1997;10(2):100–7.PubMedCrossRef
14.
go back to reference Athma P, Rappaport R, Swift M. Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet. 1996;92(2):130–4.PubMedCrossRef Athma P, Rappaport R, Swift M. Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet. 1996;92(2):130–4.PubMedCrossRef
15.
go back to reference Mehdipour P, Habibi L, Mohammadi-Asl J, Kamalian N, Mehr Azin M. Three-hit hypothesis in astrocytoma: tracing the polymorphism D1853N in ATM gene through a pedigree of the proband affected with primary brain tumor. J Cancer Res Clin Oncol. 2008;134(11):1173–80.PubMedCrossRef Mehdipour P, Habibi L, Mohammadi-Asl J, Kamalian N, Mehr Azin M. Three-hit hypothesis in astrocytoma: tracing the polymorphism D1853N in ATM gene through a pedigree of the proband affected with primary brain tumor. J Cancer Res Clin Oncol. 2008;134(11):1173–80.PubMedCrossRef
16.
go back to reference Broeks A, Urbanus JH, Floore AN, Dahler EC, Klijn JG, et al. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am J Hum Genet. 2000;66(2):494–500.PubMedCrossRef Broeks A, Urbanus JH, Floore AN, Dahler EC, Klijn JG, et al. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am J Hum Genet. 2000;66(2):494–500.PubMedCrossRef
17.
go back to reference FitzGerald MG, Bean JM, Hegde SR, Unsal H, MacDonald DJ, et al. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet. 1997;15(3):307–10.PubMedCrossRef FitzGerald MG, Bean JM, Hegde SR, Unsal H, MacDonald DJ, et al. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet. 1997;15(3):307–10.PubMedCrossRef
18.
go back to reference Izatt L, Greenman J, Hodgson S, Ellis D, Watts S, et al. Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer. Genes Chromosom Cancer. 1999;26(4):286–94.PubMedCrossRef Izatt L, Greenman J, Hodgson S, Ellis D, Watts S, et al. Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer. Genes Chromosom Cancer. 1999;26(4):286–94.PubMedCrossRef
19.
20.
Metadata
Title
Importance of ATM gene as a susceptible trait: predisposition role of D1853N polymorphism in breast cancer
Authors
Parvin Mehdipour
Marzieh Mahdavi
Javad Mohammadi-Asl
Morteza Atri
Publication date
01-09-2011
Publisher
Springer US
Published in
Medical Oncology / Issue 3/2011
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9525-0

Other articles of this Issue 3/2011

Medical Oncology 3/2011 Go to the issue